EP1937300A4 - Verfahren und zusammensetzungen zur erstellung und steuerung des effektorprofils von t-zellen durch gleichzeitiges beladen und aktivieren ausgewählter untergruppen von antigen-präsentierenden zellen - Google Patents

Verfahren und zusammensetzungen zur erstellung und steuerung des effektorprofils von t-zellen durch gleichzeitiges beladen und aktivieren ausgewählter untergruppen von antigen-präsentierenden zellen

Info

Publication number
EP1937300A4
EP1937300A4 EP06801942A EP06801942A EP1937300A4 EP 1937300 A4 EP1937300 A4 EP 1937300A4 EP 06801942 A EP06801942 A EP 06801942A EP 06801942 A EP06801942 A EP 06801942A EP 1937300 A4 EP1937300 A4 EP 1937300A4
Authority
EP
European Patent Office
Prior art keywords
cells
activation
compositions
generate
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06801942A
Other languages
English (en)
French (fr)
Other versions
EP1937300A2 (de
Inventor
Lilin Wang
Dan Smith
Bill Phillips
Adrian Bot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Multicell Immunotherapeutics Inc
Original Assignee
Multicell Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multicell Immunotherapeutics Inc filed Critical Multicell Immunotherapeutics Inc
Publication of EP1937300A2 publication Critical patent/EP1937300A2/de
Publication of EP1937300A4 publication Critical patent/EP1937300A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP06801942A 2005-08-17 2006-08-17 Verfahren und zusammensetzungen zur erstellung und steuerung des effektorprofils von t-zellen durch gleichzeitiges beladen und aktivieren ausgewählter untergruppen von antigen-präsentierenden zellen Withdrawn EP1937300A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70898005P 2005-08-17 2005-08-17
PCT/US2006/032512 WO2007022477A2 (en) 2005-08-17 2006-08-17 Methods and compositions to generate and control the effector profile of t cells

Publications (2)

Publication Number Publication Date
EP1937300A2 EP1937300A2 (de) 2008-07-02
EP1937300A4 true EP1937300A4 (de) 2009-08-12

Family

ID=37758473

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06801942A Withdrawn EP1937300A4 (de) 2005-08-17 2006-08-17 Verfahren und zusammensetzungen zur erstellung und steuerung des effektorprofils von t-zellen durch gleichzeitiges beladen und aktivieren ausgewählter untergruppen von antigen-präsentierenden zellen

Country Status (2)

Country Link
EP (1) EP1937300A4 (de)
WO (1) WO2007022477A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0922122A2 (pt) 2008-11-30 2017-08-01 Immusant Inc composições e métodos para tratamento de doença celíaca.
WO2015038624A1 (en) 2013-09-10 2015-03-19 Immusant, Inc. Dosage of a gluten peptide composition
CA2962933A1 (en) 2014-09-29 2016-04-07 Immusant, Inc. Use of hla genetic status to assess or select treatment of celiac disease
CA2971288A1 (en) 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
GB2576914A (en) * 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
WO2024126758A2 (en) 2022-12-14 2024-06-20 Ultimovacs Ab A nucleic acid molecule and a chimeric polypeptide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036087A1 (en) * 1997-02-13 1998-08-20 American National Red Cross Immunological tolerance to hiv epitopes
WO2004027049A2 (en) * 2002-09-20 2004-04-01 Astral, Inc. Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6777546B2 (en) * 1997-10-07 2004-08-17 Loma Linda University Methods and substances for preventing and treating autoimmune disease
US20020106368A1 (en) * 2000-07-28 2002-08-08 Adrian Bot Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
US6811785B2 (en) * 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036087A1 (en) * 1997-02-13 1998-08-20 American National Red Cross Immunological tolerance to hiv epitopes
WO2004027049A2 (en) * 2002-09-20 2004-04-01 Astral, Inc. Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BELL JAMES J ET AL: "Asymmetric restoration of T cell tolerance revealed by an "in trans" EAE model", FASEB JOURNAL, vol. 18, no. 4-5, 2004, & FASEB MEETING ON EXPERIMENTAL BIOLOGY: TRANSLATING THE GENOME; WASHINGTON, DISTRICT OF COLUMBIA, USA; APRIL 17-21, 2004, pages Abst. 563.7 URL - http://ww, XP009119304, ISSN: 0892-6638 *
LEGGE K L ET AL: "Multi-modal antigen specific therapy for autoimmunity", INTERNATIONAL REVIEWS OF IMMUNOLOGY, HARWOOD ACADEMIC PUBLISHERS, LONDON, GB, vol. 20, 1 January 2001 (2001-01-01), pages 593 - 611, XP002970594, ISSN: 0883-0185 *
MELO MARCO E F ET AL: "Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases.", JOURNAL OF IMMUNOLOGY, vol. 168, no. 9, 1 May 2002 (2002-05-01), pages 4788 - 4795, XP002535132, ISSN: 0022-1767 *
PHILLIPS WILLIAM J ET AL: "Recombinant immunoglobulin-based epitope delivery: A novel class of autoimmune regulators", INTERNATIONAL REVIEWS OF IMMUNOLOGY, vol. 24, no. 5-6, September 2005 (2005-09-01), pages 501 - 517, XP009119306, ISSN: 0883-0185 *
ZAGHOUANI HABIB ET AL: "Contrasting efficacy of presentation by major histocompatibility complex class I and class II products when peptides are administered within a common protein carrier, self immunoglobulin", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 23, no. 11, 1993, pages 2746 - 2750, XP009119271, ISSN: 0014-2980 *
ZAMBIDIS E T ET AL: "EPITOPE-SPECIFIC TOLERANCE INDUCTION WITH AN ENGINEERED IMMUNOGLOBULIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC., US, vol. 93, 1 May 1996 (1996-05-01), pages 5019 - 5024, XP002911069, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1937300A2 (de) 2008-07-02
WO2007022477A2 (en) 2007-02-22
WO2007022477A3 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
HUS1800021I1 (hu) Humán anti-Il-23 ellenanyagok, készítmények, eljárások és alkalmazások
HK1248523A1 (zh) 用電穿孔向細胞負載抗原
HRP20190220T1 (hr) Anti-il-23 protutijela, pripravci, postupci i upotrebe
WO2009052125A9 (en) Human anti-amyloid antibodies, compositions, methods and uses
WO2008002893A8 (en) Anti-amyloid antibodies, compositions, methods and uses
PL2679676T3 (pl) Sposoby i organizmy do sprzężonego ze wzrostem wytwarzania 1,4-butanodiolu
IL194787A0 (en) Anti-dll4 antibodies and methods using same
EP1937821A4 (de) Verfahren und organismen zur wachstumsgekoppelten herstellung von succinat
EP2190294A4 (de) Schädlingsbekämpfungszusammensetzungen sowie diese verwendende verfahren und produkte
IL187459A0 (en) Anti - mcp-1 antibodies, compositions, methods and uses
EP1937300A4 (de) Verfahren und zusammensetzungen zur erstellung und steuerung des effektorprofils von t-zellen durch gleichzeitiges beladen und aktivieren ausgewählter untergruppen von antigen-präsentierenden zellen
PL2266420T3 (pl) Peletki białka roślinnego
IL184343A0 (en) Gitr antibodies for the diagnosis of nsclc
EP1871914A4 (de) Verfahren und zusammensetzungen zur einführung von biopolymeren in zellen
WO2008030909A3 (en) Compositions and methods for imparting odor resistance and articles thereof
ZA200809100B (en) Anti-DLL4 antibodies and methods using same
EP2007409A4 (de) Regulierung der immunantwort durch modulierung der funktion von antigen-präsentierenden zellen
GB0509318D0 (en) TCR-independent activation of T cells
AU3442P (en) With Love Lavandula hybrid
AU2005900654A0 (en) Modified nutraceutical composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080317

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WANG, LILIN

Inventor name: BOT, ADRIAN

Inventor name: PHILLIPS, BILL

Inventor name: SMITH, DAN

A4 Supplementary search report drawn up and despatched

Effective date: 20090715

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091014